SEC Form 4 · accession 0000950138-18-000301
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President and CEO · Director
Period of report
Apr 2, 2018
Accepted (ET)
Apr 4, 2018 · 5:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F1 | $13.80 | Apr 2, 2018 | A | 946,003 | A | Apr 2, 2019 | Apr 2, 2028 | Ordinary Shares | 946,003 | 946,003 | D |
Explanation of responses
- F1The options vest in four equal annual installments beginning April 2, 2019.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.